Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement for Elan's Antibody-Based Therapeutics Pipeline

Wien (OTS) - 15 February 2011 - Elan plc (NYSE: ELN) and
Boehringer Ingelheim announced last week that they have entered into
a global technical development and manufacturing agreement for
antibody-based therapeutics.

Under the terms of the agreement, Boehringer Ingelheim will
perform the technical development, clinical manufacturing and all
related regulatory filing support services for antibodies discovered
by Elan. Elan will lead the discovery science, preclinical
activities, clinical development and commercialization of such
antibodies.

Dr Johannes Roebers, Senior Vice President and Head of Biologic
Strategy, Planning and Operations at Elan, said, "We are excited to
collaborate with Boehringer Ingelheim, a highly regarded and
world-class leader in biological technical development and
manufacturing. The agreement enables Elan to focus resources on
discovery and the clinical progression of our science while
leveraging the Boehringer Ingelheim's process development and
production capabilities."

Simon Sturge, Corporate Senior Vice President of the
Biopharmaceuticals Division at Boehringer Ingelheim, said, "The
combination of Elan's successful track record in the discovery and
clinical development of antibody-based therapeutics with our proven
expertise in technical development and manufacturing and in
particular our BI HEX(R) platform, will be an optimal fit. This is a
first step in our new strategy engaging our technology platforms at a
very early stage in product development. We look forward to working
with the team at Elan."

Dr Dale Schenk, Executive Vice President and Chief Scientific
Officer at Elan, said, " This collaboration with Boehringer Ingelheim
is highly compelling as it leverages our respective capabilities and
provides the opportunity to create significant value for Elan. This
business model will enable us to rapidly accelerate the advancement
of our next generation antibody programs. These programs are broad in
scope and are innovative across technology, targets and possible
disease application."

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology
company committed to making a difference in the lives of patients and
their families by dedicating itself to bringing innovations in
science to fill significant unmet medical needs that continue to
exist around the world. Elan shares trade on the New York and Irish
Stock Exchanges. For additional information about the Company, please
visit www.elan.com

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it
operates globally with 142 affiliates in 50 countries and more than
41,500 employees. Since it was founded in 1885, the family-owned
company has been committed for 125 years to researching, developing,
manufacturing and marketing novel products of high therapeutic value
for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion
euro while spending 21% of net sales in its largest business segment
Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com

Today, Boehringer Ingelheim is one of the world's leading
companies for contract development and manufacture of
biopharmaceuticals. All types of services from mammalian cell line or
microbial strain development to final drug production can be
delivered within a one-stop-shop concept. Boehringer Ingelheim
delivers services for pre-clinical development up to global market
supply with a strong commitment to its customers at its manufacturing
facilities for mammalian cell culture and microbial fermentation.
Boehringer Ingelheim has brought 18 molecules to market and has many
years of experience in multiple molecule classes such as monoclonal
antibodies, recombinant proteins, interferons, enzymes, fusion
molecules and plasmid DNA. Furthermore, high-titer platform
technologies for new antibody mimetic formats such as scaffold
proteins and antibody fragments are available for the manufacture of
customer products.

Rückfragehinweis:

Contact us: 
   [email protected]
   www.biopharma-cmo.com
   
   Media Contacts:
   
   Elan: 
   
   Niamh Lyons
   Tel.: +353 1 663 3600
   US Media Relations
   Tel.: +1 866 964 8256
   
   Boehringer Ingelheim: 
   Communications
   Vienna/Austria
   
   Inge Homolka
   Tel.: +43-1-80105-2230
   mailto:[email protected]
   
   Monika Primenz
   Tel.: +43-1-80105-2742
   mailto:[email protected]

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | IMP

print